Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humalog ® (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Is a dose conversion needed when transitioning to Humalog® (insulin lispro) 200 units/mL KwikPen® from Humalog® (insulin lispro) 100 units/mL?
When transitioning from Humalog 100 units/ml to Humalog 200 units/ml, no dose conversion is needed.
Do NOT perform dose conversion when using the Humalog (insulin lispro) 200 units/mL KwikPen (pen).1
The dose window shows the number of insulin units to be delivered and NO conversion is needed.1
Therefore, a patient receiving 20 units of Humalog 100 units/mL and transitioning to Humalog 200 units/mL Pen should dial the Pen to 20 units to administer the same 20-unit dose of insulin lispro.2
Additional information on the injected volume
1Humalog 200 units/ml KwikPen [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 15 June 2022